KR20080010400A - 키나아제 효소 활성의 억제제로서 퀴놀린과 퀸옥살린유도체 - Google Patents
키나아제 효소 활성의 억제제로서 퀴놀린과 퀸옥살린유도체 Download PDFInfo
- Publication number
- KR20080010400A KR20080010400A KR1020077024927A KR20077024927A KR20080010400A KR 20080010400 A KR20080010400 A KR 20080010400A KR 1020077024927 A KR1020077024927 A KR 1020077024927A KR 20077024927 A KR20077024927 A KR 20077024927A KR 20080010400 A KR20080010400 A KR 20080010400A
- Authority
- KR
- South Korea
- Prior art keywords
- methoxy
- compound
- yloxy
- quinolin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- FXRLWSYREBUSNL-ZDUSSCGKSA-N CC(C)(C)OC([C@H](CCO)NC(OCc1ccccc1)=O)=O Chemical compound CC(C)(C)OC([C@H](CCO)NC(OCc1ccccc1)=O)=O FXRLWSYREBUSNL-ZDUSSCGKSA-N 0.000 description 1
- KLSBLSKPSMLPRM-SIEYJJHGSA-N CC(CC1)CC1OC([C@H](CCOc1cc2nccc(Oc(cc3)ccc3NC(c3ccccc3)=O)c2cc1OC)N)=O Chemical compound CC(CC1)CC1OC([C@H](CCOc1cc2nccc(Oc(cc3)ccc3NC(c3ccccc3)=O)c2cc1OC)N)=O KLSBLSKPSMLPRM-SIEYJJHGSA-N 0.000 description 1
- FWJFGTWKMJQYIS-DOVHFGBNSA-N CC(CC=C1)C1OC([C@H](CCOc1cc2nccc(Oc(cc3)ccc3NC(c3ccccc3)=O)c2cc1OC)NC(OC(C)(C)C)=O)=O Chemical compound CC(CC=C1)C1OC([C@H](CCOc1cc2nccc(Oc(cc3)ccc3NC(c3ccccc3)=O)c2cc1OC)NC(OC(C)(C)C)=O)=O FWJFGTWKMJQYIS-DOVHFGBNSA-N 0.000 description 1
- RUWIBKJSIDPLNC-ZZHFZYNASA-N COC1C(OCC[C@@H](C(OC2CCCC2)=O)N)=Cc2nccc(Oc(cc3)ccc3NC(C3CC3)=O)c2C1 Chemical compound COC1C(OCC[C@@H](C(OC2CCCC2)=O)N)=Cc2nccc(Oc(cc3)ccc3NC(C3CC3)=O)c2C1 RUWIBKJSIDPLNC-ZZHFZYNASA-N 0.000 description 1
- JCDKKJAGDDMRME-UHFFFAOYSA-N COc(c(O)cc1ncc2)cc1c2Oc(ccc(NC(Nc1ccc(C(F)(F)F)cc1)=O)c1)c1F Chemical compound COc(c(O)cc1ncc2)cc1c2Oc(ccc(NC(Nc1ccc(C(F)(F)F)cc1)=O)c1)c1F JCDKKJAGDDMRME-UHFFFAOYSA-N 0.000 description 1
- XPBWVCQPADDCOG-UHFFFAOYSA-N COc(c(OCCCC(C(O)=O)N)cc1ncc2)cc1c2Oc(ccc(NC(Nc1ccc(C(F)(F)F)cc1)=O)c1)c1F Chemical compound COc(c(OCCCC(C(O)=O)N)cc1ncc2)cc1c2Oc(ccc(NC(Nc1ccc(C(F)(F)F)cc1)=O)c1)c1F XPBWVCQPADDCOG-UHFFFAOYSA-N 0.000 description 1
- NRKMTDOHGFBJIE-SFHVURJKSA-N COc(c(OCC[C@@H](C(O)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1CC1)=O Chemical compound COc(c(OCC[C@@H](C(O)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1CC1)=O NRKMTDOHGFBJIE-SFHVURJKSA-N 0.000 description 1
- MULJGSUCINFEKX-NRFANRHFSA-N COc(c(OCC[C@@H](C(O)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccc(C(F)(F)F)cc1)=O Chemical compound COc(c(OCC[C@@H](C(O)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccc(C(F)(F)F)cc1)=O MULJGSUCINFEKX-NRFANRHFSA-N 0.000 description 1
- WGAMYQDADHZHGG-FQEVSTJZSA-N COc(c(OCC[C@@H](C(O)=O)N)cc1ncc2)cc1c2Oc(ccc(NC(c1ccccc1)=O)c1)c1F Chemical compound COc(c(OCC[C@@H](C(O)=O)N)cc1ncc2)cc1c2Oc(ccc(NC(c1ccccc1)=O)c1)c1F WGAMYQDADHZHGG-FQEVSTJZSA-N 0.000 description 1
- HMAGDRIBLOECKK-FQEVSTJZSA-N COc(c(OCC[C@@H](C(O)=O)N)cc1ncn2)cc1c2Oc(cc1)ccc1NC(c1ccccc1)=O Chemical compound COc(c(OCC[C@@H](C(O)=O)N)cc1ncn2)cc1c2Oc(cc1)ccc1NC(c1ccccc1)=O HMAGDRIBLOECKK-FQEVSTJZSA-N 0.000 description 1
- CSRPYMJYBMYBAS-SANMLTNESA-N COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Nc(cc1)ccc1NC(c1ccccc1)=O Chemical compound COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Nc(cc1)ccc1NC(c1ccccc1)=O CSRPYMJYBMYBAS-SANMLTNESA-N 0.000 description 1
- GSUGHUFXYZJJSQ-QHCPKHFHSA-N COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccc[s]1)=O Chemical compound COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccc[s]1)=O GSUGHUFXYZJJSQ-QHCPKHFHSA-N 0.000 description 1
- SGSNRURFIBJNPZ-SANMLTNESA-N COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NS(c1ccccc1)(=O)=O Chemical compound COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NS(c1ccccc1)(=O)=O SGSNRURFIBJNPZ-SANMLTNESA-N 0.000 description 1
- QJBDJCCNMYGCBS-QFIPXVFZSA-N COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc1cc(nccc2)c2cc1 Chemical compound COc(c(OCC[C@@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc1cc(nccc2)c2cc1 QJBDJCCNMYGCBS-QFIPXVFZSA-N 0.000 description 1
- DGVRQOFMFZGCJY-OAQYLSRUSA-N COc(c(OCC[C@H](C(O)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccccc1)=O Chemical compound COc(c(OCC[C@H](C(O)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccccc1)=O DGVRQOFMFZGCJY-OAQYLSRUSA-N 0.000 description 1
- FAGSHAYSFQEJAD-AREMUKBSSA-N COc(c(OCC[C@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(Nc1ccccc1)=O Chemical compound COc(c(OCC[C@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(Nc1ccccc1)=O FAGSHAYSFQEJAD-AREMUKBSSA-N 0.000 description 1
- ANKQAOQEYGRXDH-AREMUKBSSA-N COc(c(OCC[C@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccc(C(F)(F)F)cc1)=O Chemical compound COc(c(OCC[C@H](C(OC1CCCC1)=O)N)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccc(C(F)(F)F)cc1)=O ANKQAOQEYGRXDH-AREMUKBSSA-N 0.000 description 1
- CXPOMKZQKONFEH-UHFFFAOYSA-N COc(c(OCc1ccccc1)cc1ncc2)cc1c2Oc(c(F)c1)ccc1N Chemical compound COc(c(OCc1ccccc1)cc1ncc2)cc1c2Oc(c(F)c1)ccc1N CXPOMKZQKONFEH-UHFFFAOYSA-N 0.000 description 1
- ZAHHRSCDSWSVTO-UHFFFAOYSA-N COc(c(OCc1ccccc1)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccccc1)=O Chemical compound COc(c(OCc1ccccc1)cc1ncc2)cc1c2Oc(cc1)ccc1NC(c1ccccc1)=O ZAHHRSCDSWSVTO-UHFFFAOYSA-N 0.000 description 1
- LNFQIIJBXJNNFI-UHFFFAOYSA-N Nc1cnc(NC(c2ccccc2)=O)nc1 Chemical compound Nc1cnc(NC(c2ccccc2)=O)nc1 LNFQIIJBXJNNFI-UHFFFAOYSA-N 0.000 description 1
- WHEOIEDUQSMVTO-UHFFFAOYSA-N O=C(c1ccccc1)Nc(cc1)ccc1SSc(cc1)ccc1NC(c1ccccc1)=O Chemical compound O=C(c1ccccc1)Nc(cc1)ccc1SSc(cc1)ccc1NC(c1ccccc1)=O WHEOIEDUQSMVTO-UHFFFAOYSA-N 0.000 description 1
- OXTWOIQMYKKTKJ-UHFFFAOYSA-N [O-][N+](c1c[n](CC(Nc2ccccc2)=O)nc1)=O Chemical compound [O-][N+](c1c[n](CC(Nc2ccccc2)=O)nc1)=O OXTWOIQMYKKTKJ-UHFFFAOYSA-N 0.000 description 1
- KUJDGSFHKVQDQL-UHFFFAOYSA-N [O-][N+](c1c[n](CC(O)=O)nc1)=O Chemical compound [O-][N+](c1c[n](CC(O)=O)nc1)=O KUJDGSFHKVQDQL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0509227.5A GB0509227D0 (en) | 2005-05-05 | 2005-05-05 | Intracellular enzyme inhibitors |
| GB0509227.5 | 2005-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080010400A true KR20080010400A (ko) | 2008-01-30 |
Family
ID=34685159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077024927A Ceased KR20080010400A (ko) | 2005-05-05 | 2006-05-04 | 키나아제 효소 활성의 억제제로서 퀴놀린과 퀸옥살린유도체 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8148531B2 (https=) |
| EP (1) | EP1877383B1 (https=) |
| JP (1) | JP2008540390A (https=) |
| KR (1) | KR20080010400A (https=) |
| CN (1) | CN101166726A (https=) |
| AT (1) | ATE523492T1 (https=) |
| AU (1) | AU2006243068B2 (https=) |
| BR (1) | BRPI0609857A2 (https=) |
| CA (1) | CA2606338A1 (https=) |
| GB (1) | GB0509227D0 (https=) |
| IL (1) | IL186551A0 (https=) |
| MX (1) | MX2007013276A (https=) |
| NZ (1) | NZ562520A (https=) |
| WO (1) | WO2006117552A1 (https=) |
| ZA (1) | ZA200709304B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1802591B1 (en) | 2004-10-12 | 2012-01-11 | AstraZeneca AB | Quinazoline derivatives |
| BRPI0610368A8 (pt) * | 2005-05-05 | 2015-09-08 | Glaxosmithkline Ip Dev Ltd | Modulação de enzima e de receptor |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| US8962825B2 (en) * | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| EP2262772B8 (en) * | 2008-04-16 | 2013-03-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as axl kinase inhibitors |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| JP2011241170A (ja) * | 2010-05-18 | 2011-12-01 | Mercian Corp | ビタミンｄ誘導体およびその製造方法 |
| RU2449988C1 (ru) * | 2011-04-29 | 2012-05-10 | Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) | 2,2,2-трифтор-1-трифторметилэтиловый эфир циклогексилкарбаминовой кислоты в качестве эффективного средства для селективного необратимого ингибирования карбоксилэстеразы |
| CA2846574C (en) | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors |
| CN108794411B (zh) | 2011-09-14 | 2022-06-07 | 润新生物公司 | 某些化学实体、组合物及方法 |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| CN103304489B (zh) * | 2012-03-16 | 2015-03-11 | 中国农业科学院兰州畜牧与兽药研究所 | 嘧啶苯甲酰胺类化合物及其制备和应用 |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| SI2864291T1 (sl) | 2012-06-26 | 2017-01-31 | Bayer Pharma Aktiengesellschaft | N-(4-(kinolin-4-iloksi)cikloheksil(metil))(hetero)arilkarboksamidi kot antagonisti receptorja androgena, njihova izdelava in uporaba kot medicinski izdelki |
| EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| HUE046132T2 (hu) | 2012-10-17 | 2020-02-28 | Macrophage Pharma Ltd | N-[2-{4-[6-amino-5-(2,4-difluor-benzoil)-2-oxopiridin-1(2H)-il]-3,5-difluor-fenil}etil]-l-alanin és annak tercbutil-észtere |
| US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| CN103965107B (zh) * | 2013-02-06 | 2016-08-17 | 沈阳药科大学 | 2-芳基取代喹啉类化合物及其用途 |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| EP3018165B1 (en) * | 2013-07-01 | 2019-06-12 | LG Chem, Ltd. | Polyorganosiloxane compound, method for preparing same, and copolycarbonate resin comprising same |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| NZ719185A (en) | 2013-11-01 | 2017-11-24 | Kala Pharmaceuticals Inc | Crystalline forms of therapeutic compounds and uses thereof |
| CN104072492A (zh) * | 2013-11-27 | 2014-10-01 | 苏州摩尔医药有限公司 | 一种抗肿瘤靶向治疗药物Tivozanib的合成方法 |
| CN105085433B (zh) * | 2014-05-19 | 2019-06-25 | 中国科学院上海药物研究所 | 取代酰胺苯酚类化合物及其制备方法、药物组合物和用途 |
| RU2743074C2 (ru) | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| KR20180086187A (ko) | 2015-10-05 | 2018-07-30 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료 |
| US10550135B2 (en) | 2016-03-30 | 2020-02-04 | Council Of Scientific & Industrial Research | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity |
| CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US10689362B2 (en) * | 2016-10-10 | 2020-06-23 | Development Center For Biotechnology | Quinoxaline compounds as type III receptor tyrosine kinase inhibitors |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| US20240270683A1 (en) * | 2021-06-17 | 2024-08-15 | Chandrasekhar Dayal Mudaliar | A process for preparation of an intermediate of l-glufosinate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| US6448256B1 (en) | 1999-05-24 | 2002-09-10 | University Of Massachusetts | Antibiotic prodrugs |
| US7709479B1 (en) * | 1999-09-21 | 2010-05-04 | Astrazeneca | Quinazoline derivatives and their use as pharmaceuticals |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| ATE394102T1 (de) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| PL370137A1 (en) * | 2001-11-27 | 2005-05-16 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| PA8603801A1 (es) * | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| KR20060100388A (ko) * | 2003-09-25 | 2006-09-20 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| WO2005097134A2 (en) * | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| US7732613B2 (en) * | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
-
2005
- 2005-05-05 GB GBGB0509227.5A patent/GB0509227D0/en not_active Ceased
-
2006
- 2006-05-04 AT AT06726986T patent/ATE523492T1/de not_active IP Right Cessation
- 2006-05-04 NZ NZ562520A patent/NZ562520A/en not_active IP Right Cessation
- 2006-05-04 WO PCT/GB2006/001609 patent/WO2006117552A1/en not_active Ceased
- 2006-05-04 BR BRPI0609857-6A patent/BRPI0609857A2/pt not_active IP Right Cessation
- 2006-05-04 CA CA002606338A patent/CA2606338A1/en not_active Abandoned
- 2006-05-04 US US11/918,898 patent/US8148531B2/en not_active Expired - Fee Related
- 2006-05-04 JP JP2008509501A patent/JP2008540390A/ja active Pending
- 2006-05-04 EP EP06726986A patent/EP1877383B1/en not_active Not-in-force
- 2006-05-04 AU AU2006243068A patent/AU2006243068B2/en not_active Ceased
- 2006-05-04 MX MX2007013276A patent/MX2007013276A/es active IP Right Grant
- 2006-05-04 CN CNA2006800146825A patent/CN101166726A/zh active Pending
- 2006-05-04 KR KR1020077024927A patent/KR20080010400A/ko not_active Ceased
-
2007
- 2007-10-10 IL IL186551A patent/IL186551A0/en unknown
- 2007-10-29 ZA ZA200709304A patent/ZA200709304B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008540390A (ja) | 2008-11-20 |
| ATE523492T1 (de) | 2011-09-15 |
| GB0509227D0 (en) | 2005-06-15 |
| ZA200709304B (en) | 2008-11-26 |
| BRPI0609857A2 (pt) | 2010-05-11 |
| US8148531B2 (en) | 2012-04-03 |
| AU2006243068B2 (en) | 2011-05-26 |
| AU2006243068A1 (en) | 2006-11-09 |
| WO2006117552A1 (en) | 2006-11-09 |
| IL186551A0 (en) | 2008-01-20 |
| US20090131461A1 (en) | 2009-05-21 |
| EP1877383B1 (en) | 2011-09-07 |
| EP1877383A1 (en) | 2008-01-16 |
| NZ562520A (en) | 2010-10-29 |
| CN101166726A (zh) | 2008-04-23 |
| CA2606338A1 (en) | 2006-11-09 |
| MX2007013276A (es) | 2008-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080010400A (ko) | 키나아제 효소 활성의 억제제로서 퀴놀린과 퀸옥살린유도체 | |
| US10624882B2 (en) | Rho kinase inhibitors | |
| US7932246B2 (en) | Histone deacetylase inhibitors | |
| US8466290B2 (en) | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| ES2211172T3 (es) | Derivados de benzamida y su utilizacion como inhibidores de citoquinas. | |
| WO2006117570A1 (en) | Quinoline derivatives as kinase enzyme inhibitors | |
| NZ231588A (en) | Quinazoline-4-one derivatives, medicaments | |
| CN106883213A (zh) | 一种新型egfr和alk激酶的双重抑制剂 | |
| EP1765790A1 (en) | Azine-carboxamides as anti-cancer agent | |
| JP2011518816A (ja) | Ｐｌｋインヒビター | |
| JP2004517059A (ja) | 抗腫瘍剤用の４−置換キノリン類 | |
| WO2018145621A1 (zh) | 喹啉类化合物、其制备方法及其医药用途 | |
| CN107835810A (zh) | 作为hdac1/2抑制剂的哌啶衍生物 | |
| CN111039875A (zh) | 一类hdac/alk双靶点抑制剂及其制备方法与应用 | |
| CN113880772B (zh) | 一类cdk激酶抑制剂及其应用 | |
| US10689360B1 (en) | TLR inhibitors | |
| CN112778154B (zh) | 芳基烷基醚化合物及其衍生物，制备方法、药物组合物和应用 | |
| CN111662275A (zh) | 苯磺酰胺类idh突变体抑制剂、其制备方法和用途 | |
| CN111548286B (zh) | 一种具有hdac3抑制活性的psa衍生物及其应用 | |
| KR20200012971A (ko) | 단백질 키나제 저해제로서 유용한 피리도퀴나졸린의 카르복시산 유도체 | |
| JPH06220044A (ja) | ベンズアミド誘導体 | |
| CN117343046A (zh) | 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用 | |
| CN116655595A (zh) | 2,6-哌啶二酮衍生物及其制备和用途 | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| HK1136283B (en) | Compounds for the prevention and treatment of cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20071029 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110420 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130228 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130628 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130228 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |